PubMed

Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.

Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, Goncalves E, Bricaire F, Costagliola D, Calvez V, Rouzioux C, Autran B, Katlama C, Carcelain G; ALT-ANRS CO-15 study group; DECAMUNE study group.

AIDS. 2009 Nov 26. [Epub ahead of print]PMID: 19952710 [PubMed - as supplied by publisher]Related articles

Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.

Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM; ANRS 106 Study Group.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):531-7.PMID: 19855285 [PubMed - in process]Related articles

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group.

Clin Infect Dis. 2009 Oct 15;49(8):1259-67.PMID: 19757993 [PubMed - indexed for MEDLINE]Related articles

HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome.

Prisant N, Tubiana R, Lefebvre G, Lebray P, Marcelin AG, Thibault V, Rosenblum O, Bonmarchand M, Vauthier-Brouzes D, Golmard JL, Katlama C, Poirot C.

Fertil Steril. 2009 Sep 2. [Epub ahead of print]PMID: 19732875 [PubMed - as supplied by publisher]Related articles

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.

Wirden M, Simon A, Schneider L, Tubiana R, Malet I, Ait-Mohand H, Peytavin G, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2009 Nov;64(5):1087-90. Epub 2009 Aug 27.PMID: 19717396 [PubMed - in process]Related articles

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.

AIDS. 2009 Nov 13;23(17):2289-300.PMID: 19710593 [PubMed - in process]Related articles

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.

Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte A, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group.

J Infect Dis. 2009 Sep 1;200(5):687-97.PMID: 19604043 [PubMed - indexed for MEDLINE]Related articles

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection.

Katlama C, Murphy R.

Ther Clin Risk Manag. 2009 Apr;5(2):331-40. Epub 2009 May 4.PMID: 19536321 [PubMed - in process]Related articlesFree article

A step ahead on the HIV collaboratory.

Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N, Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, Lazzarin A, McMichael AJ, Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M.

Science. 2009 Jun 5;324(5932):1264-5. No abstract available. PMID: 19498149 [PubMed - indexed for MEDLINE]Related articles

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.

Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG.

AIDS. 2009 Jul 31;23(12):1605-8.PMID: 19487903 [PubMed - indexed for MEDLINE]Related articles

Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients.

Puissant-Lubrano B, Combadière B, Duffy D, Wincker N, Frachette MJ, Ait-Mohand H, Verrier B, Katlama C, Autran B.

Vaccine. 2009 Jun 2;27(27):3576-83. Epub 2009 Apr 8.PMID: 19464537 [PubMed - indexed for MEDLINE]Related articles

[CCR5 antagonists: a new class of antiretrovirals]

Peytavin G, Calvez V, Katlama C.

Therapie. 2009 Jan-Feb;64(1):9-16. Epub 2009 May 26. Review. French. PMID: 19463248 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. Epub 2009 May 6.PMID: 19420019 [PubMed - indexed for MEDLINE]Related articles

A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.

Girard PM, Cabié A, Michelet C, Verdon R, Katlama C, Mercié P, Morand-Joubert L, Pétour P, Monchecourt F, Chêne G, Trylesinski A; COOL Study Team.

J Antimicrob Chemother. 2009 Jul;64(1):126-34. Epub 2009 Apr 29.PMID: 19403652 [PubMed - indexed for MEDLINE]Related articles

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.

Soulié C, Tubiana R, Simon A, Lambert-Niclot S, Malet I, Canestri A, Brunet C, Murphy R, Katlama C, Calvez V, Marcelin AG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):60-4.PMID: 19390328 [PubMed - indexed for MEDLINE]Related articles

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.

Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D; ANRS 121 Hippocampe study group.

AIDS. 2009 Apr 27;23(7):817-24.PMID: 19363330 [PubMed - indexed for MEDLINE]Related articles

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG.

Antivir Ther. 2009;14(1):123-9.PMID: 19320246 [PubMed - indexed for MEDLINE]Related articles

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2009 Apr;63(4):795-804. Epub 2009 Feb 16.PMID: 19221102 [PubMed - indexed for MEDLINE]Related articles

Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?

Horne R, Kovacs C, Katlama C, Clotet B, Fumaz CR, Youle M, Kulasegaram R, Fisher M, Cohen C, Slim J, Shalit P, Cooper V, Tsoukas C.

AIDS Res Ther. 2009 Feb 5;6:2.PMID: 19196474 [PubMed]Related articlesFree article

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F.

J Antimicrob Chemother. 2009 Mar;63(3):585-92. Epub 2009 Jan 15.PMID: 19147519 [PubMed - indexed for MEDLINE]Related articles